2016 ASCO Annual Meeting
Expert Point of View: W. Robert Lee, MD
Formal discussant W. Robert Lee, MD, of Duke University School of Medicine, Durham, North Carolina, placed himself firmly in the camp supporting hypofractionation as a new standard of care. “We now h...
Hypofractionation May Be Poised to Become New Standard of Care for Prostate Cancer
There has been an ongoing debate about which type of radiation therapy is preferable in the treatment of localized prostate cancer: hypofractionation (larger fractions given over 4–5 weeks) or convent...
ASCO Plenary Studies: Assessing the ‘Value’ of New Treatments
At the 2016 ASCO Annual Meeting, studies presented at the Plenary Session gave attendees new treatment strategies to employ back home. But in the emerging push to contain the cost of new cancer treat...
Quick Takes on Promising New Approaches to Treating Breast Cancer
At the 2016 ASCO Annual Meeting, researchers reported encouraging results for several new drugs and treatment strategies for breast cancer. The ASCO Post brings you brief summaries of a select few. Ab...
Selected Hematology Abstracts From the 2016 ASCO Annual Meeting
Here are several abstracts selected from the proceedings of the 2016 ASCO Annual Meeting, focusing on clinical trials on therapeutics in different types of leukemia, multiple myeloma, follicular lymph...
App Triggers Earlier Detection of Relapse, May Help Improve Survival of Patients With Lung Cancer
Web-based applications have invaded mainstream culture and grabbed the attention of multitudes of people around the world. According to a study presented at the 2016 ASCO Annual Meeting, an app may al...
Benefit Strongly Suggested With Hormonal Maintenance in Low-Grade Serous Carcinoma
In patients with low-grade serous carcinoma, maintenance hormonal therapy reduced the risk of recurrence by 77%, compared with surveillance, in a retrospective cohort from The University of Texas MD ...
PHEREXA: Benefit for Second-Line Pertuzumab Questionable
In the second-line metastatic breast cancer setting, the addition of pertuzumab (Perjeta) to trastuzumab (Herceptin)/capecitabine did not significantly improve progression-free survival, results of t...
Studies Suggest Bright Future for Combination Immunotherapy in Advanced Melanoma, but Questions Remain
Two studies presented at the 2016 ASCO Annual Meeting focused on the use of combination immunotherapy in the treatment of patients with advanced melanoma. Updated results from the phase III CheckMate...
Results of Two Practice-Changing Breast Cancer Trials Upheld
Results of two pivotal breast cancer trials reported at the 2016 ASCO Annual Meeting confirmed the practice-changing findings that resulted from earlier findings. PALOMA-2 The phase III PALOMA-2 trial...
Atezolizumab Promising in Cisplatin-Ineligible Metastatic Bladder Cancer
Atezolizumab (Tecentriq), an anti–programmed cell death ligand 1 (PD-L1) inhibitor, achieved durable responses as first-line treatment in cisplatin-ineligible patients with metastatic urothelial carci...
New Standard of Care Emerges for Anaplastic Glioma Without 1p/19q Codeletion
Adjuvant temozolomide, after radiotherapy, improves overall survival in patients with grade 3 anaplastic glioma without 1p/19q codeletion, according to a phase III EORTC (European Organization for Re...
CAR T-Cell Dose Refinement May Reduce Cytokine-Release Syndrome in Patients With Advanced Acute Lymphoblastic Leukemia
Chimeric antigen receptor (CAR) T-cell therapy has been effective in adults and children with advanced acute lymphoblastic leukemia (ALL), but along with efficacy, the treatment can stimulate cytokine...
Mixed Results With Resection of Primary Tumor in Stage IV Breast Cancer
For de novo stage IV breast cancer, does resection of the primary tumor improve outcomes? Two studies presented at the 2016 ASCO Annual Meeting reached different conclusions. A prospective randomized...
Pertuzumab-Containing Regimens Compared for Neoadjuvant Treatment in Early Breast Cancer
In patients with HER2-positive early breast cancer, pathologic complete response rates after neoadjuvant therapy were higher with docetaxel plus carboplatin plus trastuzumab (Herceptin) plus pertuzuma...
EBCTCG Analysis Identifies Recurrence Risk by Tumor Subgroup in Estrogen Receptor–Positive Breast Cancer
The risk of recurrence in estrogen receptor–positive breast cancer is known to continue after 5 years, but just how much is that risk once endocrine therapy is stopped? The Early Breast Cancer Trialis...
Combination of Nivolumab and Ipilimumab Moves Forward in NSCLC
How best to combine new immunotherapies is a burning question in oncology. A new study in the CheckMate series suggests that nivolumab (Opdivo) and ipilimumab (Yervoy) can be safely and effectively co...
Scenes From ASCO 2016
1. General views. Photo © ASCO/Matt Herp 2016; 2. Amanda Redig, MD, PhD, recipient of the 2016 Women Who Conquer Cancer Young Investigator Award. Photo © ASCO/Danny Morton 2016; 3. Himisha B...
Impressive Early Data for Rovalpituzumab Tesirine in Small Cell Lung Cancer
Initial encouraging news from a first-in-human trial suggests that the antibody-drug conjugate rovalpituzumab tesirine (Rova-T) may turn out to be a new option for patients with small cell lung cancer...
First-in-Class Antibody Reduces Gastric Cancer Recurrence
A novel immunotherapy agent, the first in its class, reduced disease progression by more than 50% when added to standard chemotherapy for patients with advanced gastric cancer, according to results fr...
Once-Daily Radiation (66 Gy) Appears No Better Than Twice-Daily Radiation (45 Gy) for Small Cell Lung Cancer
A schedule of once-daily radiation therapy (66 Gy) was no better than a twice-daily schedule (45 Gy) for optimization of chemoradiotherapy in patients with limited-stage small cell lung cancer (SCLC),...
Matching Treatment to Tumor Abnormalities Seems to Pay Off
A strategy of matching molecular abnormalities in patients’ tumors to therapies targeted to those abnormalities is gaining ground, according to preliminary results of the phase IIb MyPathway study pre...
Vast Differences Globally in Cancer Drug Retail Prices
A pilot study revealed large differences in median retail prices for 23 cancer drugs in 7 different countries, with the highest retail prices identified in the United States and the lowest, in India a...
ASCO Announces New Award Honoring Visionary Leader Allen S. Lichter, MD, FASCO
During the 2016 Annual Meeting, ASCO announced the creation of the Allen S. Lichter Visionary Leader Award to recognize ASCO members who have transformed the oncology field or significantly advanced t...
Aggressive Treatment at the End of Life Continues to Be Common
Oncologists in the United States may need to improve their efforts to reduce unnecessary care for younger patients with terminal cancer over the last 30 days of life, based on the findings of a stud...
In the Neoadjuvant Era, Intraperitoneal Chemotherapy Is of Benefit in Advanced Ovarian Cancer
The role of intraperitoneal (IP) chemotherapy in the treatment of advanced ovarian cancer has been debated for a long time. According to a new study presented at the 2016 ASCO Annual Meeting, a combin...
Expert Point of View: Sumanta K. Pal, MD, and Richard Schilsky, MD
Sumanta K. Pal, MD, an ASCO spokesperson who moderated a press briefing at the 2016 ASCO Annual Meeting, commented that the data provide key insights into the feasibility of “liquid biopsy.” “We’re ...
‘Liquid Biopsy’ Stacks Up Well to Tissue Biopsy in Detecting Tumor-Specific Mutations
So-called liquid biopsy identified cancer mutations in 85% of all advanced tumors, in the largest-ever evaluation of circulating tumor DNA (ctDNA) in the blood.1 In 49% of the cases, these biomarker...
Trastuzumab Biosimilar Shows Efficacy and Safety Comparable to Reference Product in Phase III HERITAGE Trial
A new biosimilar version of the monoclonal antibody trastuzumab (Herceptin) is getting close to the finish line in the race to develop biosimilars in oncology. The new antibody, MYL-1401O, demonstrat...
Expert Point of View: Tiffany A. Traina, MD, and Larry Norton, MD
Study discussant Tiffany A. Traina, MD, Clinical Director of the Breast Medicine Service and Associate Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor of Medicine at Weil...
Joint Analysis Confirms Benefit of Anthracyclines for High-Risk Early-Stage Breast Cancer
For the treatment of high-risk, HER2-negative early-stage breast cancer, anthracyclines were confirmed as beneficial in a joint analysis of the Anthracyclines in Early Breast Cancer (ABC) trials. Pres...
Expert Point of View: Dominique Valteau-Couanet, MD, PhD
Study discussant Dominique Valteau-Couanet, MD, PhD, of the Gustave Roussy in France, said the study was “an important step” in research, by showing “Cy-THIO/mCEM [tandem autologous stem cell transp...
For High-Risk Neuroblastoma, Two Transplants May Be Better Than One
In children with high-risk neuroblastoma, tandem autologous stem cell transplant (ASCT) improved event-free survival rates in the ANBL0532 trial from the Children’s Oncology Group. The study was pres...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results from the SQUIRE Trial (Spanish Language Version) 
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line treatment ...
Scenes From ASCO 2016
1. “The Bean” or Cloud Gate with a little ASCO color. Photo © 2016 ASCO/Todd Buchanan. 2. ASCO CEO Allen S. Lichter, MD, FASCO, introducing ASCO President Julie M. Vose, MD, MBA, FASCO, during...
ASCO 2016: CancerLinQ Extends Its Reach, Announces New Partnerships
ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ™, ASCO’s big data initiative to rapidly improve the quality of care for people with canc...
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, on Prostate Cancer: Expert Perspectives on Four Studies
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, both of the Dana-Farber Cancer Institute, discuss four key studies on high- and intermediate-risk prostate cancer, as well as localized disease (Abstracts...
Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?
Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings on rituximab maintenance therapy i...
Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App (French Language Version) 
Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discusses findings from a phase III trial on an app used between visits for early detection of symptomatic relapse ...
Sagar Lonial, MD, and Paul G. Richardson, MD, on Multiple Myeloma: Expert Perspectives on Treatment Advances
Sagar Lonial, MD, of Emory University School of Medicine, and Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discuss the top presentations on multiple myeloma delivered at this year’s me...
Celestia S. Higano, MD, and Chris Parker, MD, on the PROMIS Study of Elevated PSA
Celestia S. Higano, MD, of the University of Washington, and Chris Parker, MD, of the Royal Marsden Hospital, discuss findings from this confirmatory study evaluating the accuracy of MRI and TRUS biop...
Lisa A. Carey, MD, and Nicholas C. Turner, MD, PhD, on PALOMA-2 and -3 Study Findings in Advanced Breast Cancer
Lisa A. Carey, MD, of the University of North Carolina, and Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital and Institute of Cancer Research, discuss the efficacy of palbociclib plus fulves...
Vice President Joe Biden Addresses Attendees at ASCO 2016 Annual Meeting
Vice President Joe Biden offered remarks on the White House’s National Cancer Moonshot Initiative on Monday, June 6, to attendees at the 2016 ASCO Annual Meeting in Chicago. Essential Elements “The ...
Adjuvant Chemotherapy Improves Survival in Pancreatic Cancer
An adjuvant chemotherapy regimen improved overall survival in early-stage pancreatic cancer patients, in the large phase III European ESPAC-4 study reported at the 2016 ASCO Annual Meeting.1 The com...
Expert Point of View: Stuart A. Grossman, MD, and Deborah Schrag, MD
Formal discussant of this trial Stuart A. Grossman, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, commented that the trial did not include a best stand...
Chemoradiotherapy Improves Survival in Patients Over Age 65 With Glioblastoma: A New Standard Option?
The combination of short-course radiotherapy and temozolomide followed by maintenance with temozolomide significantly improved survival compared with short-course radiotherapy alone in newly diagnosed...
Expert Point of View: Harold J. Burstein, MD, and Ian Smith, MD
“There is a tremendous interest in longer aromatase inhibitor therapy. The Oxford Overview data, presented at ASCO, show the substantial risk of recurrence in years 5 to 15, despite an initial 5 year...
Additional 5 Years of Letrozole May Benefit Some Postmenopausal Women With Early-Stage Breast Cancer
Five years of aromatase inhibitor as upfront therapy or after tamoxifen is the current standard of care for postmenopausal women with early hormone receptor–positive breast cancer. A new trial suggest...
Clifford A. Hudis, MD, Allen S. Lichter, MD, and Richard L. Schilsky, MD, on Passing the Torch
Richard L. Schilsky, MD (right), Chief Medical Officer of ASCO, talks with incoming ASCO CEO Clifford A. Hudis, MD (left) and outgoing CEO Allen S. Lichter, MD (center) about the passing of the torch ...
Expert Point of View: Paul G. Richardson, MD
Study discussant Paul G. Richardson, MD, the RJ Corman Professor of Medicine at Harvard Medical School and the Jerome Lipper Multiple Myeloma Chair at Dana-Farber Cancer Institute, Boston, commented,...
Tait D. Shanafelt, MD, on CLL: Results From a Trial of the ECOG-ACRIN Cancer Research Group
Roisin M. Connolly, MD, on Breast Cancer Treatment Advances in 2018: Expert Perspective
Shoshana M. Rosenberg, ScD, on Quality of Life and the Impact of Breast Cancer Surgery
Hope S. Rugo, MD, on Immunotherapy for Breast Cancer: Expert Perspective
Eva M. Ciruelos, MD, PhD, on HER2-Positive Breast Cancer: Results From the PATRICIA Trial
